2026 Most-Favoured-Nation Playbook: Everything We Know About the Bilateral Drug Pricing Deals
In less than twelve months, the Trump administration turned a contested policy idea into a structural reality across the pharmaceutical
CMS GUARD Model 2026: A Complete Guide for Pharma and Biotech
December 2025 marked a defining moment in U.S. drug pricing and Medicare reimbursement policy. Alongside the GLOBE Model for Medicare
Understanding CMS’s GLOBE Model in 2026: What Pharma and Biotech Need to Know
December 2025 marked a pivotal moment in U.S. drug pricing policy. The Global Benchmark for Efficient Drug Pricing (GLOBE) Model
MFN Pricing: Mitigation Strategies for Pharma Companies in 2026
Most Favoured Nation (MFN) pricing policies are increasingly shaping global pharmaceutical launch, pricing, and access strategies. As MFN concepts link
GENEROUS Changes Everything: How the New CMS MFN Model Is Reshaping U.S. Drug Pricing in 2025–2026
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms. From binding bilateral MFN agreements
2025: Looking Back After Almost One Year of the EU JCA
The EU Health Technology Assessment Regulation (HTAR) represents one of the most significant shifts in the European health-innovation landscape in